文献速递免疫规划

使用佐剂皮肤贴片接种平台皮内递送四价细胞培养季节性流感疫苗

Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
PubMed 文献 · Vaccine · 2022-12-13

美国2021-2022年季节性流感疫苗均为四价,市场以鸡胚培养的非佐剂病毒粒抗原肌内注射为主。本研究将Flucelvax重配制并浓缩后,结合含QS-21的脂质体佐剂VAS1.1或VAS1.2,用无痛皮肤贴片VaxiPatch经皮内给药。在Sprague Dawley大鼠中,递送2 µg抗原可诱导与肌内注射相当的IgG和血凝抑制免疫应答,加VAS1.2后抗原特异性IgG滴度最高增加68倍。

要点

  • VaxiPatch贴片含36根不锈钢微针,每根载10 nL,总载量360 nL,直径1.2 cm微阵列。
  • 2 µg抗原经VaxiPatch递送在大鼠中诱导与肌内注射相当的IgG和血凝抑制应答。
  • 加VAS1.2后抗原特异性IgG滴度最高增加68倍,VAS1.1为47倍。

核心结论

  • VaxiPatch和VAS系统具有变革疫苗递送方式的潜力。

研究设计与样本

  • 临床前动物实验:将Flucelvax重配制浓缩后与VAS1.1或VAS1.2佐剂结合,用VaxiPatch贴片经皮内递送至Sprague Dawley大鼠。

主要发现

  • VaxiPatch递送2 µg抗原在大鼠中诱导与肌内注射相当的IgG和血凝抑制免疫应答。
  • 加VAS1.2后抗原特异性IgG滴度最高增加68倍,VAS1.1为47倍。
  • 四种毒株中三种血清转化改善,VAS1.1使全部四种毒株改善。
  • VaxiPatch递送后1小时仅见轻微皮肤反应原性,24小时后无皮肤反应原性。

关键数值与推荐

  • VaxiPatch微阵列含36根不锈钢微针,每根载10 nL,总载量360 nL,直径1.2 cm。
  • 重配制Flucelvax经切向流过滤浓缩后保持血凝和单放射免疫扩散效价。
  • 重配制Flucelvax装载于VaxiPatch阵列后对热应激和室温稳定性具有高水平抵抗力。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

All seasonal influenza vaccines for 2021-2022 in the US were quadrivalent and the market continues to be dominated by intramuscular delivery of non-adjuvanted, virion-derived antigens grown in chicken eggs. Up to four new egg-adapted production influenza vaccine strains must be generated each year. The introduction in 2012 of Flucelvax®, which is grown in mammalian suspension cell culture and uses vaccine production strains without adaptive mutations for efficient growth in eggs, represented a major advance in vaccine production technology. Here we demonstrate that Flucelvax can be reformulated and combined with a liposomal adjuvant containing QS-21 (Verndari Adjuvant System 1.1, VAS1.1) or QS-21 and 3D-PHAD (VAS1.2) for intradermal administration using a painless skin patch, VaxiPatch™. VAS1.2 is similar to AS01B, the adjuvant system used in Shingrix® and Mosquirix™. We show that Flucelvax, when reformulated and concentrated using tangential flow filtration (TFF), maintains hemagglutination and single radial immunodiffusion (SRID) potency. Loading the reformulated Flucelvax material onto VaxiPatch arrays conferred high levels of resistance to heat stress and room temperature stability. TFF enriched vaccine antigens were combined with VAS1.1 or VAS1.2 and dispensed in 10nL drops into the pockets of 36 (total 360 nL) stainless steel microneedles arranged in a microarray 1.2 cm in diameter. Using VaxiPatch delivery of 2 µg of antigen, we demonstrated intramusuclar-comparable IgG and hemagglutination inhibition (HAI) immune responses in Sprague Dawley® rats. With addition of VAS1.2, antigen-specific IgG titers were increased as much as 68-fold (47-fold for VAS1.1) with improvements in seroconversion for three of four strains (all four were improved by VAS1.1). TFF-reformulated antigens combined with VAS1.1 or VAS1.2 and delivered by VaxiPatch showed only minor skin reactogenicity after 1 h and no skin reactogenicity after 24 h. These data indicate that VaxiPatch and the VAS system have the potential to be transformative for vaccine delivery.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ellison TJ, Talbott GC, Henderson DR, et al. Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform. Vaccine. 2022. PMID: 36587961. doi:10.1016/j.vaccine.2022.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。